Company intelligence / Profile preview

LaNova Medicines

Shanghai, Shanghai, Chinalanovamedicines.com ↗

Ownership: Private
Development stage: Phase 3

Overview

LaNova has advanced multiple innovative biologic therapies into clinical development, including monoclonal antibodies, ADCs, and bispecifics targeting the tumor microenvironment. Lead assets include LM‑302 (Claudin18.2-targeting ADC in Phase III for gastric cancer) and LM‑299 (PD‑1/VEGF bispecific licensed globally to Merck). The company has secured numerous IND approvals and conducts trials in China, the US, and Australia. Recent results include initiation of a Phase I trial for LM‑299.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Antibody-drug conjugates (ADCs)Bispecific antibodies (BsAbs)
Industry: Biotech

Drug pipeline

14 assets

LM-108

13 more assets in the full pipeline.

Request access →

Partnerships

Merck — exclusive global license for anti-PD–1/VEGF bispecific antibody LM–299 ($588M upfront + milestones up to $2.7B)Previously had a partnership with Bristol Myers Squibb on Claudin18.2-targeting ADC but this was terminated in late 2024.

Beyond the preview

Go deeper on LaNova Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LaNova Medicines.

Explore the full profile